Program
Anti-BAFFR Monoclonal Antibody ESG206
Its studies are mostly in Lupus Erythematosus, Systemic · Purpura, Thrombocytopenic, Idiopathic, led by Shanghai Escugen Biotechnology.
Drug pageAnti-BAFFR Monoclonal Antibody ESG206: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Feb 25, 20255 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Escugen Biotechnology | 53 open or running | phase 2since Feb 25, 2025 | Feb 18, 2022 | Dec 31, 2027phase 2 · NCT07375524 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 18, 2022First study: phase 1 study in B-cell Lymphoid MalignanciesFirst studyNCT05263739
- Apr 10, 2023Phase 1 study in B-cell Lymphoid MalignanciesNCT05822843 · 13 enrolled · China
- Feb 25, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT06853444 · 84 planned · China
- Jan 21, 2026Phase 2 study in Primary Sjögren SyndromeNCT07375524 · 40 planned · China
- Aug 7, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07760155 · 40 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Primary Sjögren SyndromeNCT07375524
- Mar 31, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07760155
TargetBeta
TNFRSF13C →read by rule
“A monoclonal antibody that is directed against the tumor-associated antigen (TAA) B-cell activating factor receptor (BAFFR; tumor necrosis factor receptor superfamily member 13C; TNFRSF13C; BLyS receptor 3; BR3), ”NCIt, by rule
Other programs on TNFRSF13C
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ianalumab | Novartis | phase 3 | 34 |
| Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199rule | Eli Lilly | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07760155Lupus Erythematosus, Systemic · China | 2 | Not yet recruiting | Mar 31, 2028 | 40 |
| NCT07375524Primary Sjögren Syndrome · China | 2 | Not yet recruiting | Dec 31, 2027 | 40 |
| NCT06853444Purpura, Thrombocytopenic, Idiopathic · China | 2 | Recruiting | Mar 31, 2026 | 84 |
| NCT05822843B-cell Lymphoid Malignancies · China | 1 | Completed | Jan 22, 2025 | 13 |
| NCT05263739B-cell Lymphoid Malignancies | 1 | Withdrawn | Aug 2026 | 0 |
How it is read
Names in the registry
- “ESG206”, 10 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
- Purpura, Thrombocytopenic, Idiopathic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.